How the iconic North Sydney Olympic Pool put local council in deep financial debt
But lately the achievements at North Sydney Olympic Pool haven't been quite so magnificent.
When it finally ends, a two-year renovation budgeted at $57 million will have taken five years and cost $122 million.
It's put the local council $56 million in debt, prompting it to consider some unpopular methods of clawing back cash, like increasing rates by 90 per cent, charging people to watch New Year's Eve fireworks, and selling public streets to private schools.
The council has also had to curtail its public works budget and can't afford essential works like repairing leaking roofs at childcare and community centres.
All in one of the nation's wealthiest areas.
North Sydney Mayor Zoe Baker isn't happy about it.
As a councillor, Ms Baker voted against the pool redevelopment. As mayor, she has to find the cash to pay for it.
"Just in the last three years we've had to defer, each year, $12 million on capital works on council assets," she said.
This year the council is also trying to find $6 million in savings.
"The council agreed very reluctantly to ticket access for New Year's Eve and Blues Point Reserve, and that's in order to find $300,000 to offset the cost of delivery of New Year's Eve."
At the same council meeting, councillors had to choose between funding a seawall repair, or fixing North Sydney Oval's broken PA system.
Former North Sydney lap swimmer Clare Payne says the pool's once-tight community of early morning swimmers have lost touch with each other.
Closures for renovations at the other two nearest public pools — at Willoughby and Mrs Macquarie's Chair — have forced those swimmers even further apart.
Ms Payne was upset back in 2019 when the council announced the North Sydney pool would be closed for up to two years.
"That felt quite devastating." she told 7.30.
"I didn't really want to even process that because I thought this is just going to be too long. I hate the fact that it's closing like this, especially both pools."
The second pool was a 25-metre indoor pool that sat atop the grandstand designed by architect Ken Maher.
His 2001 redevelopment on the heritage grandstand won several architecture awards.
In 2019 the council announced it would be demolished, along with the entire grandstand.
Mr Maher said he was "shattered, frankly, and because it seemed to be for no really good reason".
The grandstand had concrete cancer — but Mr Maher says the building could have been saved.
"It wasn't falling down," he said.
"It may have meant that there was work that had to be done to repair the structure underneath that was suffering, but it's not unusual that concrete structures that are having concrete cancer are repaired."
The redevelopment was championed by then-mayor Jilly Gibson, who retired last year.
Jessica Keen is the sole remaining councillor who voted for the redevelopment. She says council staff made a business case for the pool, which she approved in good faith.
"I voted for a $60 million pool, not $122 million. There is a vast difference in that budget," she said.
An independent review of the project by accounting firm PWC found that the problems started even before work commenced.
Among the problems identified by the review:
The builder, Icon, says the council's design team have made hundreds of changes to the project.
Icon blames the council for the failure of structural steel in the new indoor pool building, atop the rebuilt grandstand. That steel had to be pulled down and replaced.
Icon and the council are also in a legal dispute over $28 million in cost overruns.
Mayor Baker says the scale of the project was always too much for council to take on.
"It started as a $28 million project. It morphed effectively on the floor of council into a $58 million project … there were literally councillors getting up on the floor of council and saying, 'I'd like a creche, and I would like this,' and so the scope of the brief was being expanded in an ad hoc way," Mayor Baker said.
"There was no reporting back about how much that would cost and how council would fund it."
Mayor Baker says the pool will be handed back to the council later this year and should be open to the public in the first quarter of 2026, once the fit-out is finished.
She is relieved the saga is finally coming to an end.
"For me it's bittersweet, because there's absolutely no satisfaction in 'I told you so,'" she said.
"I don't think the cost of that $122 million to our community for the things we've had to forego and the impossible decisions that we're now having to make because of the financial impacts is worth it.
"I was always an advocate for doing a much more modest approach to the pool redevelopment."
Mr Maher, the architect of the demolished 25m pool, doubts he'll be returning to swim at the rebuilt site.
"I don't think I'll go there. I think I'll just feel too negative about it," he said.
Does he have any sense of schadenfreude?
"I think the the tragedy of the project is the impact it's had on the community, no access to the pool for five years or more, huge increase in cost," he said.
Ms Payne, the former North Sydney pool swimmer, is looking forward to the reopening and trying the complex's new 25m indoor pools.
She sometimes swims at Balmoral, where the sea temperature is currently a chilly 15 degrees.
"It doesn't necessarily get any easier, I think, swimming in cold water. It's bracing, it's invigorating. But it will definitely be nice to get a pool back — especially an indoor pool."
Watch 7.30, Mondays to Thursdays 7:30pm on ABC iview and ABC TV
Do you know more about this story? Get in touch with 7.30 here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
a few seconds ago
- ABC News
More scrutiny for Australia's child care sector
Australia's child care sector is set to come under further scrutiny in the coming weeks as another inquiry puts the sector under the microscope.

News.com.au
a few seconds ago
- News.com.au
ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month
The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US subject to CLIA waiver Clever Culture Systems rose 81.3% in July on news global pharmaceutical giant Novo Nordisk purchased one of its flagship APAS Independence instruments for evaluation The healthcare sector rose 9.05% in July to be the best of the 11 ASX sectors. A turn up for the books to be sure. While remaining the worst performing sector YTD – up just 1.81% – the S&P ASX Health Care index was in recovery mode in July. The sector was buoyed by a roughly 13% rise in its biggest name blood products giant CSL (ASX:CSL), which drives much of the index. Morgans' healthcare analyst Iain Wilkie said there appeared to be a strong sector rotation on the ASX in July. "During July there certainly was a rotation out of usual strong sectors like financials and more into healthcare and the miners," he told Stockhead. "Healthcare has been beaten down for quite a long while now and is starting to look attractive. "I don't think there was anything specific in terms of a catalyst to drive the rotation." Looking ahead, Wilkie noted the sector may face continued pressure with US President Donald Trump again threatening tariffs " at a very, very, high rate, like 200%" on imported pharmaceuticals. "Trump has again thrown his weight around but until it actually hits we'll see," Wilkie said. He said US tariffs shouldn't affect companies like CSL, which is one of the world's largest manufacturers of plasma products. "Although the US collects over 60% of the world's plasma, it lacks sufficient domestic capacity to process it into finished therapies," he said. "As a result, imported plasma products are critical to meeting national demand. "Introducing tariffs on these products would likely be counterproductive as they wouldn't foster viable domestic alternatives and could drive up costs, potentially limiting patient access and causing harm." How ASX biotechs performed in July CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP PAB Patrys Limited $ 0.002 181.8% 6.9 LDX Lumos Diagnostics $ 0.073 170.4% 55.4 NSB Neuroscientific $ 0.235 170.1% 79.8 NXS Next Science Limited $ 0.140 109.0% 41.7 NOX Noxopharm Limited $ 0.110 103.7% 30.7 CMB Cambium Bio Limited $ 0.425 102.4% 8.2 DVL Dorsavi Ltd $ 0.028 86.7% 27.3 ICR Intelicare Holdings $ 0.013 85.7% 6.3 CC5 Clever Culture $ 0.029 81.3% 56.9 EMD Emyria Limited $ 0.049 75.0% 28.1 CU6 Clarity Pharma $ 4.370 74.8% 1,471.5 HMD Heramed Limited $ 0.012 71.4% 10.5 MX1 Micro-X Limited $ 0.083 69.4% 54.0 TTX Tetratherix Limited $ 5.020 66.2% 131.7 CAN Cann Group Ltd $ 0.016 60.0% 9.8 NYR Nyrada Inc. $ 0.370 54.2% 77.8 VBS Vectus Biosystems $ 0.06 50.0% 3.2 CSX Cleanspace Holdings $ 0.760 46.2% 59.5 MSB Mesoblast Limited $ 2.380 43.8% 3,046.3 AVE Avecho Biotech Ltd $ 0.005 42.9% 15.9 HIQ Hitiq Limited $ 0.020 42.9% 9.9 AYA Artryalimited $ 1.025 42.4% 116.7 ANR Anatara Ls Ltd $ 0.007 40.0% 1.5 ATH Alterity Therap Ltd $ 0.014 40.0% 128.9 CBL Control Bionics $ 0.040 37.9% 12.1 EYE Nova EYE Medical Ltd $ 0.150 36.4% 41.2 IBX Imagion Biosys Ltd $ 0.015 36.4% 3.0 IPD Impedimed Limited $ 0.047 34.3% 93.4 RCE Recce Pharmaceutical $ 0.388 33.6% 108.4 NTI Neurotech Intl $ 0.020 33.3% 21.0 VFX Visionflex Group Ltd $ 0.00 33.3% 6.7 AT1 Atomo Diagnostics $ 0.018 28.6% 14.2 AHC Austco Healthcare $ 0.370 27.6% 137.0 TRP Tissue Repair $ 0.240 26.3% 14.5 SOM SomnoMed Limited $ 0.815 25.4% 171.8 1AD Adalta Limited $ 0.003 25.0% 2.8 ADR Adherium Ltd $ 0.005 25.0% 9.0 BIT Biotron Limited $ 0.003 25.0% 3.3 CUV Clinuvel Pharmaceut. $ 12.970 25.0% 617.5 FRE Firebrickpharma $ 0.077 24.2% 17.5 CMP Compumedics Limited $ 0.315 23.5% 66.3 NEU Neuren Pharmaceut. $ 17.290 22.5% 2,150.6 ILA Island Pharma $ 0.170 21.4% 40.8 ATX Amplia Therapeutics $ 0.240 20.0% 111.9 DOC Doctor Care Anywhere $ 0.125 19.0% 47.7 EBR EBR Systems $ 1.410 18.0% 514.6 LTP Ltr Pharma Limited $ 0.340 17.2% 60.6 PAR Paradigm Bio. $ 0.355 16.4% 136.1 LGP Little Green Pharma $ 0.115 16.2% 35.1 M7T Mach7 Tech Limited $ 0.380 15.2% 89.3 ALC Alcidion Group Ltd $ 0.115 15.0% 154.4 NC6 Nanollose Limited $ 0.077 14.9% 24.1 CYC Cyclopharm Limited $ 1.040 14.3% 113.4 SPL Starpharma Holdings $ 0.100 13.6% 43.9 MVF Monash IVF Group Ltd $ 0.800 13.5% 309.8 SNT Syntara Limited $ 0.060 13.2% 97.6 CSL CSL Limited $ 270.900 13.1% 128,514.7 PME Pro Medicus Limited $ 321.890 12.9% 33,058.3 CVB Curvebeam Ai Limited $ 0.080 12.7% 33.2 IMM Immutep Ltd $ 0.270 12.5% 385.3 MVP Medical Developments $ 0.610 11.9% 64.8 TRJ Trajan Group Holding $ 0.800 11.9% 121.9 GLH Global Health Ltd $ 0.076 11.8% 4.5 VIT Vitura Health Ltd $ 0.07 11.3% 47.0 PIQ Proteomics Int Lab $ 0.360 10.8% 57.3 IRX Inhalerx Limited $ 0.042 10.5% 9.0 IDT IDT Australia Ltd $ 0.098 10.1% 40.7 NUZ Neurizon Therapeutic $ 0.170 9.7% 81.2 PGC Paragon Care Limited $ 0.400 9.6% 653.8 RHY Rhythm Biosciences $ 0.059 9.3% 17.4 1AI Algorae Pharma $ 0.006 9.1% 10.1 CTQ Careteq Limited $ 0.012 9.1% 2.8 AHX Apiam Animal Health $ 0.565 8.7% 103.0 ARX Aroa Biosurgery $ 0.630 8.6% 224.3 OCC Orthocell Limited $ 1.275 8.5% 309.7 MAP Microbalifesciences $ 0.092 8.2% 47.4 PSQ Pacific Smiles Grp $ 1.670 8.1% 269.9 PNV Polynovo Limited $ 1.290 7.9% 858.4 RMD ResMed Inc. $ 42.450 7.9% 61,930.3 PTX Prescient Ltd $ 0.047 6.8% 38.7 REG Regis Healthcare Ltd $ 8.370 6.8% 2,545.6 TYP Tryptamine Ltd $ 0.03 6.7% 44.6 SDI SDI Limited $ 0.883 6.3% 104.6 COH Cochlear Limited $ 318.520 6.0% 20,541.2 RHC Ramsay Health Care $ 38.770 5.7% 8,808.5 IDX Integral Diagnostics $ 2.670 5.1% 1,001.8 IMC Immuron Limited $ 0.064 4.9% 16.9 OCA Oceania Healthc Ltd $ 0.660 4.8% 461.5 EBO Ebos Group Ltd $ 37.250 4.7% 7,552.6 RAD Radiopharm $ 0.023 4.5% 54.4 ACW Actinogen Medical $ 0.024 4.3% 76.3 IIQ Inoviq Ltd $ 0.385 4.1% 43.5 AGH Althea Group $ 0.026 4.0% 21.4 IME Imexhs Limited $ 0.300 3.4% 15.8 CYP Cynata Therapeutics $ 0.155 3.3% 37.3 SHL Sonic Healthcare $ 27.610 3.1% 13,532.2 FPH Fisher & Paykel H. $ 34.090 1.4% 19,481.0 CTE Cryosite Limited $ 0.750 0.7% 36.6 VLS Vita Life Sciences.. $ 2.26 0.4% 124.4 ACR Acrux Limited $ 0.016 0.0% 7.0 BP8 Bph Global Ltd $ 0.002 0.0% 2.1 EMV Emvision Medical $ 1.740 0.0% 150.1 EOF Ecofibre Limited $ 0.020 0.0% 7.6 EPN Epsilon Healthcare $ 0.024 0.0% 7.2 NAN Nanosonics Limited $ 4.050 0.0% 1,196.3 OSX Osteopore Limited $ 0.011 0.0% 2.6 TD1 Tali Digital Limited $ 0.001 0.0% 4.2 TRI Trivarx Ltd $ 0.008 0.0% 5.0 TRU Truscreen $ 0.016 0.0% 12.3 ACL Au Clinical Labs $ 2.760 -0.7% 536.1 CGS Cogstate Ltd $ 1.730 -0.9% 292.9 MYX Mayne Pharma Ltd $ 4.950 -1.0% 405.4 ANN Ansell Limited $ 29.950 -1.1% 4,410.5 AFP Aft Pharmaceuticals $ 2.400 -1.2% 259.6 RGT Argent Biopharma Ltd $ 0.080 -1.2% 4.7 RAC Race Oncology Ltd $ 1.160 -1.3% 198.9 SNZ Summerset Grp Hldgs $ 10.300 -1.3% 2,513.8 HLS Healius $ 0.770 -1.9% 548.2 ALA Arovella Therapeutic $ 0.098 -2.0% 117.7 BMT Beamtree Holdings $ 0.245 -2.0% 72.6 ONE Oneview Healthcare $ 0.245 -2.0% 185.7 4DX 4Dmedical Limited $ 0.235 -2.1% 136.2 COV Cleo Diagnostics $ 0.380 -2.6% 48.8 RHT Resonance Health $ 0.038 -2.6% 17.5 AVH Avita Medical $ 1.670 -2.6% 217.6 SIG Sigma Health Ltd $ 2.890 -3.3% 32,726.4 PYC PYC Therapeutics $ 1.240 -4.2% 729.1 IXC Invex Ther $ 0.085 -4.5% 6.9 OIL Optiscan Imaging $ 0.105 -4.5% 87.7 ZLD Zelira Therapeutics $ 0.41 -6.8% 4.9 MDR Medadvisor Limited $ 0.075 -7.4% 43.8 BDX Bcaldiagnostics $ 0.058 -7.9% 20.5 GSS Genetic Signatures $ 0.330 -9.6% 76.1 CDX Cardiex Limited $ 0.036 -10.0% 18.7 PER Percheron $ 0.009 -10.0% 10.9 AGN Argenica $ 0.680 -10.5% 86.1 OSL Oncosil Medical $ 1.070 -10.8% 20.2 ECS ECS Botanics Holding $ 0.008 -11.1% 11.0 PEB Pacific Edge $ 0.085 -11.5% 75.9 IVX Invion Ltd $ 0.096 -12.7% 8.2 EZZ EZZ Life Science $ 2.030 -13.2% 99.1 TLX Telix Pharmaceutical $ 21.050 -13.8% 6,991.3 AVR Anteris Technologies $ 5.130 -16.4% 179.8 DXB Dimerix Ltd $ 0.470 -18.3% 285.1 SHG Singular Health $ 0.300 -18.9% 93.5 IMR Imricor Med Sys $ 1.225 -19.4% 324.2 MEM Memphasys Ltd $ 0.004 -20.0% 7.9 PCK Painchek Ltd $ 0.035 -22.2% 66.3 CHM Chimeric Therapeutic $ 0.003 -25.0% 11.4 VHL Vitasora Health Ltd $ 0.03 -28.2% 46.4 UCM Uscom Limited $ 0.01 -31.3% 2.9 UBI Universal Biosensors $ 0.02 -31.4% 7.2 IMU Imugene Limited $ 0.270 -38.9% 77.2 BOT Botanix Pharma Ltd $ 0.150 -53.1% 289.3 Patrys (ASX:PAB) rose ~182% in July after announcing a solid June quarter including a board restructure, $300,000 capital raise and actively pursuing partnering and licensing opportunities for both of its oncological cell therapy deoxymab assets. In July Patrys also announced a fully underwritten, pro-rata non-renounceable entitlement offer of three fully paid ordinary shares for every four shares held at an issue price of $0.001 per Share, together with on free-attaching new share for every four shares applied for and issued, to raise up to ~$1.78m. Lumos Diagnostics (ASX:LDX) rose more than 170% in July after l anding a landmark six-year distributor deal worth hundreds of millions of dollars to sell its rapid point-of-care diagnostic FebriDx in the US market. The FebriDx product is a simple test able to differentiate between bacterial and non-bacterial acute respiratory infections. The lucrative US licensing deal with Hong-Kong based PHASE Scientific could see Lumos net up to to US$317m (~A$487m), and has been described as one of the largest distribution deals of its type to be done by an ASX-listed point-of-care diagnostics company. Adelaide-based Clever Culture Systems (ASX:CC5), rose 81.3% in July after announcing global pharmaceutical giant Novo Nordisk had purchased one of its flagship APAS Independence instruments for evaluation. The machine will be delivered to Novo's central team in Denmark, where it will undergo a full-scale evaluation to assess its suitability for deployment across Novo's global manufacturing network. The APAS Independence uses AI technology to automate one of the most time-consuming parts of microbiology, analysing agar plates for contamination. Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) was up 74.8% in July after completing a large $203m institutional placement at a 15% premium to the company's 15-day average price, to fund their clinical program. Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company". 'I have never done a deal that fast,' Taylor said. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group .' At Stockhead, we tell it like it is. While Lumos Diagnostics and Clever Culture Systems are Stockhead advertisers, the companies did not sponsor this article. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

News.com.au
a few seconds ago
- News.com.au
Kurrinda Bloodstock director Sean Driver attempting Everest-Kosciuszko double with Private Harry and Boston Rocks
Kurrinda Bloodstock's Sean Driver is planning an audacious bid for the mega-rich The Everest-The Kosciuszko double this spring carnival. Driver's exciting, unbeaten sprinter Private Harry has already secured a start in the Group 1 $20m The TAB Everest (1200m) at Royal Randwick on October 23. On the same day, the leading syndicator and part-owner is hoping Boston Rocks will be lining up in the $2m The Kosciuszko. The Nathan Doyle -trained Private Harry, winner of his five starts including the Group 1 The Galaxy, will be sporting a 'new look' when he returns to racing this season. Driver said the sprint sensation has made significant physical development during his spell and the four-year-old has bulked up with '60-80kg of natural muscle'. 'Private Harry has spelled really well, he looks great,'' Driver said. 'The plan is for him to have two barrier trials starting with Rosehill next Monday and then an exhibition gallop before he resumes in The Shorts (September 20). He will then start in the Premiere Stakes (October 4) before The Everest.'' Private Harry was the first horse into The Everest field after slot-holder Yulong Investments purchased a 50 per cent share in the brilliant sprinter following his The Galaxy win. Driver revealed Private Harry's jockey Ashley Morgan will be wearing the familiar white, pale blue colours of Kurrinda Bloodstock in The Shorts and Premiere Stakes. But for The Everest, Morgan is set to wear a specially designed hybrid set of silks that has the Yulong colours of bottle green, white checked sleeves and white cop adorned with a Kurrinda Bloodstock star logo on the jockey's front and back. With Private Harry's Everest campaign locked in, Driver is now keen to get the underrated Boston Rocks into The Kosciuszko. Boston Rocks, who is trained by Matthew Dale, won successive city races in Sydney and Melbourne in autumn and is set to resume racing on Saturday. Driver said Boston Rocks has been entered for a Benchmark 88 Handicap (1000m) at Rosehill Gardens and also for a Benchmark 100 Handicap (1000m) at Moonee Valley. 'Boston Rocks doesn't like it any worse than a Soft 6 so we will probably accept for both races and see how the tracks are for Saturday,'' he said. Driver also revealed promising three-year-old Hidden Motive, a stablemate of Private Harry, is being readied for a return to racing in the Listed The Rosebud at Rosehill Gardens on August 16.